Browsing Tag
Natco Pharma Limited
4 posts
Lupin and Natco FDA approval puts #LUPIN in focus as oncology generic pipeline strengthens
Lupin and Natco won FDA approval for Eribulin generic. #LUPIN investors now face the real test: launch timing and U.S. pricing.
NATCO Pharma (NSE: NATCOPHARM) wins CDSCO approval for semaglutide as FDA compliance risks recede at its API unit
NATCO Pharma Limited secures CDSCO approval for semaglutide as U.S. FDA risks ease. Find out what this means for growth, execution, and investors.
Natco Pharma completes full US generic Revlimid lineup with new lenalidomide strengths
Natco Pharma and Teva Pharmaceuticals launch 2.5 mg and 20 mg generic lenalidomide in US, completing their Revlimid portfolio for multiple myeloma treatment.
Natco Pharma launches NATGEN insecticide after Delhi High Court approval
Natco Pharma launches NATGEN insecticide in India after Delhi High Court approval, targeting a ₹2,000 crore Chlorantraniliprole market.